claudin-3 Inhibitors
Claudin-3, a crucial component of tight junctions, plays a pivotal role in maintaining epithelial barrier integrity. The modulation of claudin-3 expression is a subject of intense research, and several chemicals have been identified as inhibitors, either directly or indirectly impacting its regulation. These inhibitors exert their effects through diverse biochemical and cellular pathways, showcasing the intricate interplay governing tight junction dynamics. One notable class of claudin-3 inhibitors includes AMP-activated protein kinase (AMPK) activators such as A769662. By enhancing cellular glucose uptake and metabolism through AMPK activation, these inhibitors indirectly impact claudin-3 expression by disrupting the mechanistic target of rapamycin (mTOR) signaling pathway. This disruption alters the transcriptional landscape associated with tight junction regulation, highlighting the interconnectedness of cellular energetics and claudin-3 dynamics.
Furthermore, synthetic tetrapeptides like Epithalon emerge as indirect inhibitors by modulating the p53 pathway. Through the activation of telomerase and subsequent telomere elongation, Epithalon induces p53-mediated apoptosis, influencing cellular senescence and tight junction protein expression, including claudin-3. This exemplifies the cross-talk between telomere maintenance and the regulatory networks governing tight junction integrity. Additionally, kinase inhibitors such as Trametinib, targeting the MAPK pathway, showcase a targeted approach to indirect claudin-3 inhibition. By disrupting downstream signaling events, these inhibitors alter the expression of transcription factors involved in tight junction regulation, demonstrating the specificity required for effective modulation of claudin-3. In conclusion, the chemical class of claudin-3 inhibitors encompasses a diverse array of compounds that exert their effects through intricate pathways, providing a nuanced understanding of how tight junction dynamics, particularly claudin-3 expression, can be modulated.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A769662, an AMP-activated protein kinase (AMPK) activator, indirectly inhibits claudin-3 by affecting cellular energy homeostasis. By activating AMPK, A769662 enhances cellular glucose uptake and metabolism, leading to a decrease in mTOR signaling. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
AZD7762 is a selective checkpoint kinase 1 (CHK1) inhibitor that indirectly influences claudin-3 expression by disrupting the DNA damage response pathway. Inhibition of CHK1 leads to unrepaired DNA damage, activating the p53 pathway and inducing apoptosis. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, indirectly modulates claudin-3 expression by targeting the MAPK pathway. It disrupts the downstream signaling of MAPK, affecting transcription factors like c-Jun and c-Fos. These factors, in turn, regulate the expression of tight junction proteins, including claudin-3. | ||||||
NDGA (Nordihydroguaiaretic acid) | 500-38-9 | sc-200487 sc-200487A sc-200487B | 1 g 5 g 25 g | $109.00 $384.00 $2190.00 | 3 | |
NDGA inhibits claudin-3 indirectly by interfering with the NF-κB pathway. As a potent antioxidant, NDGA modulates oxidative stress, leading to the inhibition of NF-κB activation. Given that NF-κB is involved in the transcriptional regulation of claudin-3, NDGA disrupts this pathway, negatively impacting the expression of claudin-3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly influences claudin-3 expression by targeting the PI3K/Akt pathway. Inhibition of PI3K leads to reduced Akt activation, affecting downstream targets involved in tight junction regulation. | ||||||
Salinomycin | 53003-10-4 | sc-253530 sc-253530C sc-253530A sc-253530B | 5 mg 10 mg 25 mg 100 mg | $162.00 $241.00 $406.00 $474.00 | 1 | |
Salinomycin indirectly inhibits claudin-3 by disrupting Wnt signaling, an upstream pathway associated with tight junction regulation. As a Wnt/β-catenin pathway inhibitor, salinomycin influences the nuclear translocation of β-catenin, a key regulator of claudin-3 expression. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-DG indirectly inhibits claudin-3 expression by disrupting glycolysis and cellular energetics. As a glucose analog, 2-DG competitively inhibits glucose uptake, leading to metabolic stress. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly modulates claudin-3 expression by targeting the mTOR pathway. Inhibition of mTOR by rapamycin leads to downstream effects on protein synthesis and cellular proliferation, impacting the expression of tight junction proteins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 mitogen-activated protein kinase (MAPK) inhibitor, indirectly influences claudin-3 expression by targeting the p38 MAPK pathway. Inhibition of p38 MAPK disrupts downstream signaling cascades, affecting transcription factors involved in tight junction regulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly inhibits claudin-3 expression by disrupting the PI3K/Akt pathway. Inhibition of PI3K by wortmannin leads to reduced Akt activation, influencing downstream targets associated with tight junction regulation. | ||||||